Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya.
Lugano, D. I.; Kutima, B.; Kimani, M.; Sigilai, A.; Gitonga, J. N.; Karani, A.; Akech, D.; Karia, B.; Ziraba, A. K.; Maina, A.; LAMBISIA, A. W.; Omuoyo, D.; Mugo, D.; Lucinde, R.; Newman, J.; Bailey, D. K.; Nduati, E.; Githinji, G.; Agoti, C. N.; Bejon, P.; Scott, J. A. G.; Agweyu, A. J.; Kagucia, W.; Warimwe, G. M.; Sande, C. J.; Ochola-Oyier, L. I.; Nyagwange, J.
Show abstract
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and March 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant 96%
- Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera 95%
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma 95%
Similar papers in this journal
- SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern 96%
- Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies 96%
- Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2 95%
Similar papers in this journal
- Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals 96%
- Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant 95%
- Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.